Arthur Joseph Murphy Iii, MD in Drumright, OK - Orthopaedic Surgery

Arthur Joseph Murphy Iii, MD is a Orthopaedic Surgery physician based in Drumright, Oklahoma. Arthur Joseph Murphy Iii is licensed to practice in Oklahoma (license number 11726) and his current practice location is 500 Lou Allard Dr, Drumright, Oklahoma. He can be reached at his office (for appointments etc.) via phone at (918) 352-2555.

NPI number for Arthur Joseph Murphy Iii is 1760570543 and his current mailing address is 2424 E 29th St, Tulsa, Oklahoma. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1760570543.

Contact Information

	Arthur Joseph Murphy Iii, MD
	500 Lou Allard Dr, Drumright, OK 74030-4800
	(918) 352-2555
	(918) 352-4709

Physician's Profile

Full Name	Arthur Joseph Murphy Iii
Gender	Male
Speciality	Orthopaedic Surgery
Location	500 Lou Allard Dr, Drumright, Oklahoma
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1760570543
Provider Enumeration Date: 10/10/2006
Last Update Date: 07/08/2007

Medical Identifiers

Medical identifiers for Arthur Joseph Murphy Iii such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1760570543	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207X00000X	Orthopaedic Surgery	11726 (Oklahoma)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Arthur Joseph Murphy Iii is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Arthur Joseph Murphy Iii, MD 2424 E 29th St, Tulsa, OK 74114-5619 Ph: (918) 749-7645	Arthur Joseph Murphy Iii, MD 500 Lou Allard Dr, Drumright, OK 74030-4800 Ph: (918) 352-2555

News Archive

E.U. CHMP issues positive opinion for use of Celgene's REVLIMID/dexamethasone MM drug

Celgene International Sàrl was notified today that the E.U. Committee for Medicinal Products for Human Use (CHMP), on behalf of the European Medicines Agency (EMA) has concluded an Article 20 review of REVLIMID and issued a positive opinion for the use of REVLIMID in combination with dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

UnitedHealth plan to boost dividends may draw criticism

The Associated Press: UnitedHealth Group has drastically raised dividends paid to shareholders - from $35 million to $560 million a year - in a move that may draw criticism for profits that rose alongside soaring health costs. "There is somewhat of a risk, especially in the current fragile reform environment, that says, 'Why is UnitedHealth declaring a dividend instead of lowering health care costs for its members?'" said analyst Tom Carroll.

State highlights: Md., Minn. see small business health insurance rate changes; Texas sues AstraZeneca over Seroquel marketing

Some small businesses in Maryland will see a small drop in health insurance premiums next year, while others will pay as much as 11 percent more to cover their workers, according to rates released by state regulators Friday. The rates, which go into effect in January, only apply to small firms with up to 50 employees, and not to large or self-insured firms or individuals buying coverage on the state's health insurance exchange. Evergreen Health Cooperative sought no rate increase, and Aetna Health Inc. will raise rates only slightly, according to the rate information released by the Maryland Insurance Administration. Some UnitedHealthcare premiums will drop by about 2.5 percent (Cohn, 10/10).

Sepracor to present clinical study data of STEDESA at the 2009 AES meeting

Sepracor Inc. today announced that clinical study data for STEDESA™ (eslicarbazepine acetate) will be presented at the 2009 annual meeting of the American Epilepsy Society (AES) in Boston. Seven posters describing new safety analyses will be presented at the Hynes Convention Center during the formal poster session on Saturday, December 5, 2009 between 1:00 pm and 8:00 pm EST.

Arthur Joseph Murphy Iii, MD - Orthopaedic Surgery in Drumright, OK